ABSTRACT
Due to the side effects posed by conventional chemotherapy, metronomic chemotherapy came into being. Metronomic chemotherapy, which is characterized by the frequent and regular administration of lower doses of chemotherapeutic agents, has gained significant attention as a novel approach to cancer treatment. This chapter explores the concept of metronomic chemotherapy as a multitargeted therapy. Unlike traditional chemotherapy or high-dose chemotherapy, metronomic chemotherapy aims to disrupt tumor growth by leveraging the principles of anti-angiogenesis, immunomodulation, and tumor dormancy. The chapter delves into underlying mechanisms through which metronomic chemotherapy exerts its effects, including inhibition of tumor angiogenesis by targeting endothelial cells, its impact on immune cells and the tumor microenvironment, and its potential to induce tumor dormancy. Moreover, the chapter discusses preclinical and clinical studies that have examined the efficacy of metronomic chemotherapy across various cancer types, highlighting its promising results in terms of prolonged disease stabilization, reduced drug resistance, and improved patient quality of life. Ultimately, this chapter underscores the significance of metronomic chemotherapy as a multitargeted therapeutic approach that has the potential to revolutionize cancer treatment paradigms, offering new avenues for enhancing treatment efficacy and patient well-being.
